A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[F-18]fluoro-D-glucose in murine models of breast cancer

被引:39
作者
Aliaga, Antonio [1 ]
Rousseau, Jacques A. [1 ]
Cadorette, Jules [1 ]
Croteau, Etienne [1 ]
van Lier, Johan E. [1 ]
Lecomte, Roger [1 ]
Benard, Francois [1 ]
机构
[1] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Med Nucl & Radiobiol, Sherbrooke Mol Imaging Ctr, Sherbrooke, PQ J1H 5N4, Canada
基金
加拿大健康研究院;
关键词
positron emission tomography; PET; small animal PET; estrogen receptor; breast cancer; 2-deoxy-2-[F-18]fluoro-D-glucose; tumor metabolism; chemotherapy; hormone therapy;
D O I
10.1007/s11307-007-0091-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: We used small animal positron emission tomography (PET) imaging to monitor the time-course of tumor metabolic response to hormone and chemotherapy in a murine model of hormone-sensitive breast cancer. Procedures: Estrogen receptor positive murine mammary carcinomas were inoculated in Balb/c mice. Small animal PET imaging using 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) was used to assess tumor metabolic activity. Imaging was done before and at days 1, 7, and 14 after the administration of doxorubicin, methotrexate, letrozole, or placebo. The tumor uptake of FDG was calculated from a region-of-interest drawn around the tumor. Results: All treatments resulted in a decrease in tumor growth rate and end volume compared to untreated control. FDG uptake was also markedly decreased after treatment although a flare reaction was observed on PET at day 7, the intensity of which varied according to the treatment modality. Conclusion: PET imaging is sensitive to detect early changes associated with therapy in murine breast cancer models. A flare reaction was observed 7 days after the initiation of therapy.
引用
收藏
页码:144 / 150
页数:7
相关论文
共 18 条
[1]   Breast cancer models to study the expression of estrogen receptors with small animal PET imaging [J].
Aliaga, A ;
Rousseau, JA ;
Ouellette, R ;
Cadorette, J ;
van Lier, JE ;
Lecomte, R ;
Bénard, F .
NUCLEAR MEDICINE AND BIOLOGY, 2004, 31 (06) :761-770
[2]   Imaging in breast cancer:: Single-photon computed tomography and positron-emission tomography [J].
Bénard, F ;
Turcotte, É .
BREAST CANCER RESEARCH, 2005, 7 (04) :153-162
[3]  
Clarke R, 2001, PHARMACOL REV, V53, P25
[4]   Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer [J].
Dowsett, M .
ENDOCRINE-RELATED CANCER, 2001, 8 (03) :191-195
[5]  
GREENWALD ES, 1983, CANCER TREAT REP, V67, P405
[6]  
HAMACHER K, 1986, J NUCL MED, V27, P235
[7]  
KEYES JW, 1995, J NUCL MED, V36, P1836
[8]  
Lanari C, 2001, CANCER RES, V61, P293
[9]   Initial results from the Sherbrooke avalanche photodiode positron tomograph [J].
Lecomte, R ;
Cadorette, J ;
Rodrigue, S ;
Lapointe, D ;
Rouleau, D ;
Bentourkia, M ;
Yao, R ;
Msaki, P .
IEEE TRANSACTIONS ON NUCLEAR SCIENCE, 1996, 43 (03) :1952-1957
[10]   DESIGN AND ENGINEERING ASPECTS OF A HIGH-RESOLUTION POSITRON TOMOGRAPH FOR SMALL ANIMAL IMAGING [J].
LECOMTE, R ;
CADORETTE, J ;
RICHARD, P ;
RODRIGUE, S ;
ROULEAU, D .
IEEE TRANSACTIONS ON NUCLEAR SCIENCE, 1994, 41 (04) :1446-1452